Mumbai: Pharmaceutical and biotechnology firm Wockhardt on Thursday said it has received approval from the US drug regulator Food and Drug Administration for marketing the alcohol-free syrup Ranitidine, which is used in the treatment of ulcers and hyperactivity.
In a filing to the Bombay Stock Exchange (BSE) Wockhardt said it has received final approval from the United States Food and Drug Administration (USFDA) for marketing the alcohol-free syrup containing 15mg/ml Ranitidine, which is used in the treatment of ulcers and hyperactivity.
In addition, the company has also received tentative approval for an alcohol containing formulation of Ranitidine. The patent of this product would expire on 26 May this year.
Wockhardt has received 23 Abbreviated New Drug Approvals (ANDA) by the USFDA for 2008.
Shares of the company closed at Rs81.50, down 0.97% on the BSE index.